ADORA2B and glaucoma: In particular, metabotropic serotoninergic and adenosine receptors, such as the 5-hydroxytryptamine 5A (5-HT5A) and adenosine A2B receptors, were identified as innovative (not yet investigated) drug targets for glaucoma treatment.